← Back to Clinical Trials
Recruiting NCT07417605

NCT07417605 Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiation Inflammation in Head Neck SCC Treated by Radiotherapy.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07417605
Status Recruiting
Phase
Sponsor University Hospital, Brest
Condition Head & Neck Squamous Cell Carcinoma
Study Type OBSERVATIONAL
Enrollment 180 participants
Start Date 2026-04-13
Primary Completion 2029-06-13

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 180 participants in total. It began in 2026-04-13 with a primary completion date of 2029-06-13.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This multicenter prospective observational study will evaluate the value of dynamic FDG-PET LAFOV imaging during the initial therapeutic assessment of a head and neck cancer 3 months after completion of curative radiotherapy.

Eligibility Criteria

Inclusion Criteria: * Adult patient ≥ 18 years of age * Presenting with head and neck squamous cell carcinoma * Completed curative treatment with external radiation therapy * Eligible for dynamic LAFOV FDG-PET scan for therapeutic evaluation at 3 months * Having given consent for the end-of-treatment consultation Exclusion Criteria: * Hypersensitivity to 18F-FDG or other excipients contained in the contrast agent * Pregnancy or breastfeeding * History of treated upper gastrointestinal tract cancer * Other histology * Incomplete RTE treatment regimen * Refusal to participate

Contact & Investigator

Central Contact

Ronan ABGRAL, Pr

✉ ronan.abgral@chu-brest.fr

📞 +332 98 22 30 69

Frequently Asked Questions

Who can join the NCT07417605 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Head & Neck Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07417605 currently recruiting?

Yes, NCT07417605 is actively recruiting participants. Contact the research team at ronan.abgral@chu-brest.fr for enrollment information.

Where is the NCT07417605 trial being conducted?

This trial is being conducted at Brest, France, Brest, France, Brest, France.

Who is sponsoring the NCT07417605 clinical trial?

NCT07417605 is sponsored by University Hospital, Brest. The trial plans to enroll 180 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology